Clinical trials
Breast cancer clinical trials
Cancer that forms in the cells of the breast, the most common cancer in women. We’re tracking 2,460 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07299825RecruitingPhase 2
Study of A166 for advanced HER2-positive breast cancer
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Zhenzhou, HenanAges 18–75 - NCT07616440Recruiting
Ultrasound drug delivery with chemotherapy for HER2-positive breast cancer
This study tests a new technique that uses focused ultrasound to deliver cancer drugs directly to breast tumors, combined with standard chemotherapy. The goal is to improve treatment effectiveness for HER2-positive breast cancer before surgery.
Hangzhou, ZhejiangAges 18–70 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT04281641Recruiting
Testing marker-guided treatment before surgery for HER2-positive breast cancer
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07616427RecruitingPhase 2
New drug plus hormone therapy for HER2-positive breast cancer
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06711055Recruiting
Taxane plus targeted therapy for early HER2-positive breast cancer
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
Beijing, Beijing MunicipalityAges Any age - NCT06313086RecruitingPhase 3
New drug vs. T-DM1 for HER2-positive advanced breast cancer
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT05883852RecruitingPhase 3
HER2-positive breast cancer trial for women with lymph node spread
This Phase 3 trial compares two post-surgery drug plans for HER2-positive early breast cancer that has spread to nearby lymph nodes. It may help reduce cancer recurrence by testing which regimen works better after surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07056686Enrolling by invitation
Early breast cancer detection for Syrian women
This study aims to find breast cancer early in Syrian women living in the middle region. It's a program to help detect cancer before symptoms appear, so treatment can start sooner.
HomsAges 18–65 - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06722612Recruiting
Chemo plus targeted therapy for high-risk HER2+ early breast cancer
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
Beijing, Beijing MunicipalityAges Any age - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT07604571RecruitingPhase 1
Testing IEV407 for Advanced Hormone-Sensitive Breast Cancer
This study tests a new drug called IEV407, either alone or combined with existing hormone therapies, in people with advanced breast cancer that is hormone-receptor positive and HER2 negative. The trial aims to find the right dose and see if this combination helps people whose cancer has stopped responding to previous treatments.
Dallas, TexasAges 18–100 - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75 - NCT07531693Recruiting
Improving Outcomes in Early Hormone-Positive Breast Cancer
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Erlangen, BavariaAges 18 years+ - NCT07215364Recruiting
Exercise and quality of life in early breast cancer on hormone therapy
This trial tests if a supervised exercise program can improve quality of life for people with early-stage breast cancer who are currently taking hormone therapy (aromatase inhibitors with or without CDK4/6 inhibitors). It aims to see if exercise helps reduce side effects like fatigue and pain.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT07731477Recruiting
Virtual reality mindfulness for anxiety in breast cancer chemo
This study tests if using virtual reality for mindfulness exercises can help reduce anxiety, improve comfort, sleep, and fatigue in women with breast cancer who are about to start chemotherapy. It compares VR mindfulness to standard care.
Ankara, AnkaraAges 18 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07257484RecruitingPhase 4
Tirzepatide study for breast cancer survivors with obesity
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
New York, New YorkAges 18 years+ - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer?
- Yes. Clin2 currently lists 2,460 recruiting breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.